Journal
HAEMATOLOGICA
Volume 103, Issue 8, Pages 1390-1402Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2017.186619
Keywords
-
Categories
Funding
- Fondazione Cariplo [2012/0683, 2015/0603]
- Associazione Italiana per la Ricerca sul Cancro [MFAG 10607, IG.20312, IG 14687]
- Italian Ministry of Health [GR-2011-02347324, GR-2013-02356522]
- National Institutes of Allergy and Infectious Diseases
- Humanitas Research Hospital
- Fondazione Italiana per la Ricerca sul Cancro
- Fondazione Umberto Veronesi
Ask authors/readers for more resources
Natural killer cells are the first lymphocyte population to reconsti-tute early after non-myeloablative and T cell-replete haploidenti-cal hematopoietic stem cell transplantation with post-transplant infusion of cyclophosphamide. The study herein characterizes the transient and predominant expansion starting from the second week following haploidentical hematopoietic stem cell transplantation of a donor-derived unconventional subset of NKp46neg-low/CD56dim/CD16neg natural killer cells expressing remarkably high levels of CD94/NKG2A. Both transcription and phenotypic profiles indicated that unconventional NKp46neg-low/CD56dim/CD16neg cells are a distinct natural killer cell subpopulation with features of late stage differentiation, yet retaining prolifera-tive capability and functional plasticity to generate conventional NKp46pos/CD56bright/CD16neg-low cells in response to interleukin-15 plus interleukin-18. While present at low frequency in healthy donors, unconventional NKp46neg-low/CD56dim/CD16neg cells are greatly expanded in the seven weeks following haploidentical hematopoietic stem cell transplantation, and express high levels of the activating receptors NKG2D and NKp30 as well as of the lytic granules Granzyme-B and Perforin. Nonetheless, NKp46neg-low/CD56dim/CD16neg cells displayed a markedly defective cytotoxicity that could be reversed by blocking the inhibitory receptor CD94/NKG2A. These data open new and important perspectives to better understand the ontogenesis/homeostasis of human natural killer cells and to develop a novel immune-therapeutic approach that targets the inhibitory NKG2A check-point, thus unleashing natural killer cell alloreactivity early after haploidentical hematopoietic stem cell transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available